Evgen Pharma Share Discussion Threads

[moneymunch] 23/4/2021 11:15

1.6m!!!????

[pdt] 23/4/2021 10:22

I have been doing some reading to try and understand how Evgen's approach may be beneficial. In summary NRF2 is suppressed in COVID patients and autophagy is compromised. Treatment with SFX01 should upregulate NRF2 and restore autophagy. This research paper is a good read explaining why that is important; "Role of Nrf2 and Autophagy in Acute Lung Injury" hTTps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905711/ I have bought a few more since there must be a reasonable chance of seeing some benefit from SFX01 even if it is only a marginal effect. Results next week? GLA.

[moneymunch] 23/4/2021 08:09

times now showing 17.32pm and 17.48pm ;0)

[moneymunch] 23/4/2021 08:06

and now 2 x 800k trades at 8.2p timed at 7.15am 2 seconds apart....hmmmm ;-[

[moneymunch] 23/4/2021 07:10

All smoke and mirrors and about time we had some clarity on whether a trade is a buy or sell, although on LSE the first one is listed "Ordinary" and the second one is listed "Ordinary - Delayed Publication", and so looks like one buy for 898K imho and not a Cancellation or Deletion"....and hopefully from some one very confident in SFX-01's efficacy data for Covid/ARDS. Gl ;-)

[donaferentes] 22/4/2021 21:16

Could be a deal placed then cancelled. I've heard that ADVFN shows that as 2 deals. You can check on the LSE site.

[moneymunch] 22/4/2021 20:45

I think it's one buy for 898k, but listed twice with the time the order was placed and the time the order was filled....the accumulation of cheap shares continues imho and maybe a TR1 to follow. Gl :-)

[mesquida] 22/4/2021 20:29

I doubt very much that they are both buys, more likely that it is an inter fund transfer.

[moneymunch] 22/4/2021 18:56

2 x 898k delayed trades priced as buys at 8.3p!!!??? Gla ;-)

[clocktower] 22/4/2021 16:29

It's a slow plod up hill but one step at a time, so just sitting and waiting for good news. It will come.

[moneymunch] 22/4/2021 14:36

No news yet muddy from Prof Chalmers on that one.

[on target] 22/4/2021 14:15

House broker FCAP seem stuck on the offer again despite some decent buying.

[muddy_40] 22/4/2021 14:11

MM. You mentioned the STOP covid trial earlier. Brensocatib in the STOP-Covid Trial!!!??? Gl ;-) I thought the readout was supposed to be February for that in a past Prof Chalmers tweet. I need to look back his twitter feed

[moneymunch] 22/4/2021 14:06

Prof Chalmers is one of the chairs for the following event 29th April 2021, and so an opportune time to report on interim efficacy data on SFX-01's Covid/ARDS patient trials. Gla :-) A full-day virtual event dedicated to COVID-19, where top level faculty will share the latest advances, data and best practices relating to SARS-CoV-2 and COVID-19. “This event brings together world-leaders tackling COVD-19 and how different digital approaches to big data  will help us to defeat the pandemic. hTtps://www.ersnet.org/events/covid-19-state-of-the-art-dragon-imi-project/?preview_id=129976 will help us to defeat the pandemic” ;– 

[moneymunch] 22/4/2021 14:06

News could be close. :-)

[on target] 22/4/2021 11:31

Spot on moneymunch re: the attitude of some, yet the number of studies supporting the hypothesis is getting hard to ignore. Just off the top of my head: - Study using sulforaphane to successfully treat ARDS (that's ACUTE respiratory distress syndrome, for those people who still think a compound found in plants can't possibly have an effect on acute conditions) in rabbits - Korean study showing a statistical correlation between kimchi consumption and improved COVID outcomes - Recent John Hopkins study suggesting anti-viral action in addition to the anti-inflammatory Nrf2 that was already known

[moneymunch] 22/4/2021 11:24

Evgen are still very much under the radar and even viewed as a pseudoscience with its focus on Broccoli and green vegetables by some , and with efficacy for Covid/Ards a big ask and a long list of promising drugs that have failed to meet expectations, and so no doubt the market is awaiting Prof Chalmers efficacy assessment, and if he reports good news then those invested now will reap the rewards as the share price is likely to multi-bag and market and investor interest thereafter will be exceptional and SFX 01 will be the number one contender for Boris's Covid Treatment Task Force....Tick Tock. Gla :-)

[on target] 22/4/2021 11:04

Just had a little top-up and interestingly had to split the order. It seems the apparent stock available on the offer at the moment is a bit of a mirage, and shrinks when you go to buy for real.

[awise355] 22/4/2021 11:02

It's crazy can't last forever

[on target] 22/4/2021 10:47

I'm amazed at the lack of interest in this stock, given the ducks lining up here and the very low EV?

[moneymunch] 22/4/2021 10:33

Maybe more than a dream Bumpa, and exactly what John Hopkins University research was suggesting with Sulforaphane, administered to treat Covid and administered to prevent Covid, and SFX-01 patent protected is the only potent clinical grade form. Could be bigger than we imagine if efficacy is proven and correlates to John Hopkins. Gl :-)

[bumpa33] 22/4/2021 10:09

The most widely recognizable of analgesics and NSAID. Imagine Sulforadex in that category. Nice to dream :)

[on target] 22/4/2021 09:51

Copied from a post on the DDDD thread: "BBC Radio 2 had a feature yesterday with regard to Covid treatments. The consensus was that a simple tablet that can be taken at home will be the answer in the future. Comparisons were made with paracetamol and aspirin."

[pdt] 22/4/2021 09:29

Interesting research paper on the benefits of upregulating NRF2 which supports Evgen. "SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate" hTTps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532469/ In conclusion, NRF2 agonists induce a distinct IFN-independent antiviral program that is broadly effective in limiting virus replication and in suppressing the pro-inflammatory responses of human pathogenic viruses, including SARS-CoV2. In summary, NRF2 agonists are plausible broad-spectrum antiviral and anti-inflammatory agents.

[moneymunch] 22/4/2021 07:22

and also interesting that prof Chalmers has yet to make any twitter comment on Boris's proposals, which is his usual way on any significant Covid developments. Gla ;-)